Vaginal bleeding is the single most common symptom when stage 1A endometrial cancer comes back, but recurrence after this early-stage diagnosis is uncommon in the first place. Studies put the overall recurrence rate somewhere between about 4% and 8%, depending on tumor grade and other features. Because the risk is low, many women finish treatment and never face a recurrence, yet knowing what to watch for matters because catching a recurrence early can make a real difference in how treatable it is.
How Often Stage 1A Endometrial Cancer Actually Recurs
Stage 1A means the tumor was confined to the inner lining of the uterus or invaded less than halfway through the muscular wall, with no spread to lymph nodes or distant organs. That confinement is the main reason recurrence rates are relatively low. A study of 222 patients with the lowest-risk profile, stage 1A grade 1 endometrioid cancer, found that about 8% experienced a recurrence, though their five-year overall survival dropped sharply compared with those who stayed disease-free.1PubMed Central. Recurrence risk factors in stage IA grade 1 endometrial cancer A Danish nationwide survey of stage 1A patients reported an even lower rate of roughly 4%, with vaginal recurrences making up about two-thirds of all relapses.2PubMed. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey
A larger population-based cohort of over 1,600 women with endometrioid endometrial cancer found an overall recurrence rate around 8%, with a median time to recurrence of roughly 22 months. Women who never recurred had five-year overall survival above 90%, while those who developed a vaginal-only recurrence still had a five-year survival of about 77%. For recurrences at other sites, that number fell to about 36%.3Gynecologic Oncology. Recurrence and survival in endometrioid endometrial cancer – a population-based cohort study The takeaway is that recurrence is uncommon at stage 1A, and when it does happen, where it shows up matters enormously for outcomes.
Vaginal Bleeding and Other Local Symptoms
The most frequent site of recurrence after early-stage endometrial cancer is the vaginal vault, meaning the top of the vagina where the cervix used to be before hysterectomy. The hallmark symptom is vaginal bleeding or spotting, which is notable because most women who have had a hysterectomy for endometrial cancer do not expect to see any bleeding at all. In one study of nearly 300 stage 1 patients who had completed treatment, four of the six stage 1A recurrences presented with vaginal bleeding from a vault mass.4PubMed Central. Stage one endometrioid endometrial adenocarcinoma: is there a role of traditional hospital follow-up in the detection of cancer recurrence in women after treatment?
In a large Scandinavian study of over 2,600 women with early-stage endometrial cancer, about two-thirds of all recurrences were symptomatic at the time of detection, and vaginal bleeding was the most prevalent symptom.5PubMed. Detection of recurrence in early stage endometrial cancer – the role of symptoms and routine follow-up Beyond bleeding, local recurrence can also cause pelvic pain or pressure, a feeling of heaviness in the lower abdomen, or pain during urination. Some women notice watery or blood-tinged vaginal discharge rather than frank bleeding. Any new vaginal bleeding after hysterectomy should prompt a call to your doctor, even if you had the lowest-risk cancer on paper.
What Distant Recurrence Feels Like
A smaller fraction of stage 1A recurrences show up at distant sites rather than locally. The lungs are the most common distant target. Lung metastases from endometrial cancer often appear as multiple small nodules on both sides, though sometimes a single nodule appears that can initially look like a new primary lung cancer.6PubMed Central. Lung Metastases in Endometrial Carcinoma: A Deadly Twist Symptoms of lung recurrence include a persistent cough that does not improve, shortness of breath, or coughing up blood. One published case described a woman who had been disease-free for nearly five years after surgery for stage 1A endometrial cancer before developing a chronic cough and coughing up blood; imaging revealed bilateral lung masses.7PubMed Central. Late distant recurrence of endometrial cancer in the lung after 5 years of radical surgery: a case report
Bone metastases, while less common, tend to announce themselves with new, persistent bone pain that worsens over time and does not respond to usual pain management. One case report documented new-onset bone pain just six months after finishing treatment for endometrial adenocarcinoma, which turned out to be metastatic disease confirmed by a whole-body bone scan.8PubMed Central. Endometrial adenocarcinoma with bone metastasis: A case report Liver and brain metastases are rarer still but can produce symptoms such as abdominal pain, jaundice, persistent headaches, or neurological changes like confusion or weakness on one side of the body.
One particularly unusual distant recurrence involved a woman whose stage 1 endometrial cancer came back more than a decade after her original surgery, presenting as a mass in the colon. She experienced worsening crampy abdominal pain, constipation, thinner stools, and significant unintentional weight loss.9PubMed Central. Obstructing Colonic Mass: A Case of Recurrent Endometrial Cancer Cases like these are rare but illustrate that endometrial cancer can reappear in unexpected places and after surprisingly long intervals.
When Recurrences Tend to Appear
Most recurrences of early-stage endometrial cancer show up within the first two to three years after treatment. The population-based cohort study cited earlier found a median time to recurrence of about 22 months, with the range stretching from just a few months to nearly five years.10Gynecologic Oncology. Recurrence and survival in endometrioid endometrial cancer – a population-based cohort study That is why follow-up visits are typically scheduled most frequently in the first two to three years and then gradually spaced out.
Not all distant sites develop at the same speed. A multicenter French study found that brain metastases tended to appear earliest, at a median of about seven months after treatment, while bone metastases had a median of 19 months and lymph node metastases above the diaphragm could take over two years.11PubMed. Incidence, patterns and prognosis of first distant recurrence after surgically treated early stage endometrial cancer Late recurrences beyond five years are well documented but uncommon. The lung-recurrence case mentioned earlier, appearing nearly five years out, sits at the edge of what most surveillance schedules are designed to catch.12PubMed Central. Late distant recurrence of endometrial cancer in the lung after 5 years of radical surgery: a case report
Asymptomatic Recurrence and Why It Matters
About a third of recurrences are found before the woman notices any symptoms, usually during routine follow-up exams or imaging. In the Scandinavian study, roughly 2.3% of the entire cohort had an asymptomatic recurrence, and these women had significantly better three-year survival than those whose recurrence was symptomatic: about 80% versus 54%.13PubMed. Detection of recurrence in early stage endometrial cancer – the role of symptoms and routine follow-up The likely explanation is that asymptomatic recurrences tend to be caught at a smaller volume and before they have spread further, which makes them more amenable to curative treatment.
This finding has fed an ongoing debate among gynecologic oncologists about the value of routine surveillance visits and whether they should include imaging. Many centers rely primarily on physical exams and symptom review, with imaging reserved for women who report new symptoms. The argument for adding imaging is that it catches these silent recurrences earlier. The argument against is that recurrence is rare enough in stage 1A that widespread imaging generates false alarms and anxiety in the large majority of women who will never recur. There is no universal consensus, and practice varies by institution.
How Recurrence Is Confirmed
When symptoms or a physical exam raises suspicion, imaging is the next step. A PET/CT scan is particularly good at picking up endometrial cancer recurrence. A systematic review pooling data from multiple studies found that PET/CT had a sensitivity above 95% and a specificity above 92% for detecting recurrence on a per-patient basis.14PubMed. Accuracy of 18-F-FDG PET imaging in the follow up of endometrial cancer patients: systematic review and meta-analysis of the literature Conventional imaging like CT scans or MRI and the blood marker CA-125 perform considerably less well on their own. One comparison study found that conventional imaging had sensitivity of about 46% and CA-125 even lower, while PET/CT reached 100% sensitivity in that cohort.15Revista Española de Medicina Nuclear e Imagen Molecular (English Edition). The value of FDG-PET/CT in the post-treatment evaluation of endometrial carcinoma: A comparison of PET/CT findings with conventional imaging and CA 125 as a tumour marker That said, a tissue biopsy is almost always needed to confirm recurrence before treatment decisions are made.
Risk Factors That Make Recurrence More or Less Likely
Not all stage 1A cancers carry the same recurrence risk. A few features in the original pathology report carry outsized importance.
Lymphovascular space invasion, or LVSI, is one of the strongest predictors. LVSI means cancer cells were seen inside the small blood or lymph vessels within the uterine tissue. In a study of stage 1 node-negative endometrioid cancers, women with LVSI had a recurrence rate of about 15% compared with about 7% for those without it, and distant metastasis dominated the recurrence pattern in the LVSI-positive group. On multivariate analysis, LVSI nearly quintupled the risk of recurrence.16PubMed Central. The Impact of Lymphovascular Space Invasion on Recurrence and Survival in FIGO Stage I Node-Negative Endometrioid Endometrial Cancer
Tumor histology also matters. The classic endometrioid type at low grade carries the best prognosis, with five-year overall survival around 88% and disease-specific survival above 95%.17PubMed Central. Outcomes of Adjuvant Therapy for Stage IA Serous Endometrial Cancer Serous endometrial cancer, even when caught at stage 1A, behaves more aggressively and has significantly worse recurrence-free and overall survival. This is an important distinction because some women are told they have “stage 1A” and assume the prognosis is uniformly excellent, when the histological subtype changes the picture considerably.
Molecular classification is increasingly used to refine risk. Tumors with POLE mutations have the best outlook. In one study, no recurrences or deaths were seen in POLE-mutant cancers over more than five years of follow-up.18British Journal of Cancer. A clinically applicable molecular-based classification for endometrial cancers On the other end of the spectrum, tumors with p53-abnormal profiles had a five-year recurrence-free survival of only 50%, even among high-risk endometrial cancers receiving adjuvant treatment. Mismatch-repair-deficient and “no specific molecular profile” tumors fell in between.19Annals of Oncology. LBA63 – Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy Molecular subtype was a stronger predictor of survival than traditional histology in at least one study.20PubMed Central. Incorporating Molecular Classification When Stratifying the Survival Risk of Patients with High-Grade Endometrial Carcinomas If your pathology report includes molecular testing, it gives both you and your doctor a sharper picture of what level of vigilance makes sense.
Treatability When Recurrence Happens
Where the recurrence shows up largely determines how treatable it is. Vaginal vault recurrences, the most common type after stage 1A disease, are often curable. In one randomized trial, 87% of women with an isolated vaginal relapse were treated with curative intent, usually with a combination of external radiation and brachytherapy. Among those women, 89% achieved a complete remission, and 77% were still in remission at last follow-up. The three-year survival after vaginal relapse was 73%, compared with just 8% after a pelvic relapse and 14% after distant relapse.21PubMed. Survival after relapse in patients with endometrial cancer: results from a randomized trial
Local and locoregional recurrences can generally be treated with curative intent through surgery, radiation, or a combination. Distant recurrences are managed differently, typically with systemic therapy such as chemotherapy or hormonal treatment, and the goal shifts more toward controlling disease and maintaining quality of life.22PubMed Central. Recurrent Endometrial Cancer: Local and Systemic Treatment Options Survival after distant recurrence varies by site. The French multicenter study found that women with lymph node-only distant recurrence had a three-year survival around 83%, while liver metastases carried the worst prognosis at 0% three-year survival in that cohort.23PubMed. Incidence, patterns and prognosis of first distant recurrence after surgically treated early stage endometrial cancer
Newer therapies, including immunotherapy and targeted agents, are changing the landscape for recurrent endometrial cancer, particularly for women whose tumors have mismatch-repair deficiency or high microsatellite instability. These treatments were not reflected in many of the older survival statistics, so outcomes for distant recurrence are likely improving, though long-term data are still accumulating.
The Role of Adjuvant Vaginal Brachytherapy
Many women with stage 1 endometrial cancer receive adjuvant vaginal brachytherapy after surgery as a way to reduce the risk of vault recurrence. The evidence suggests it is effective at keeping vaginal recurrence rates very low. In a single-institution study of 157 stage 1-2 patients treated with brachytherapy, only one vaginal recurrence occurred over a median follow-up of nearly seven years, with five-year cause-specific survival above 96% for stage 1 patients.24PubMed. Recurrences and toxicity after adjuvant vaginal brachytherapy in Stage I-II endometrial cancer: A monoinstitutional experience A larger study comparing different brachytherapy regimens found vaginal recurrence rates between about 1% and 5%, with no significant differences between regimens on multivariate analysis.25PubMed. Do vaginal recurrence rates differ among adjuvant vaginal brachytherapy regimens in early-stage endometrial cancer?
Brachytherapy does not eliminate the risk of distant recurrence, however, because it only treats the local area. When recurrences did occur in brachytherapy-treated patients, they tended to be nodal or distant rather than vaginal.26PubMed. Recurrences and toxicity after adjuvant vaginal brachytherapy in Stage I-II endometrial cancer: A monoinstitutional experience This fits the broader pattern seen in trials: isolated pelvic recurrences after adequate local treatment are rare, and most failures happen at distant sites, often alongside local spread.27International Journal of Gynecological Cancer. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy
Living with Fear of Recurrence
Even when the statistics are reassuring, the psychological burden of having had cancer does not neatly track the numbers. In a cohort of gynecologic cancer survivors, about 30% scored in the high range for fear of cancer recurrence.28PubMed Central. Psychosocial predictors of fear of cancer recurrence in a cohort of gynecologic cancer survivors That fear can make every ache, twinge, or episode of spotting feel like evidence of recurrence. It can also lead to hypervigilance that paradoxically increases anxiety without improving outcomes.
One randomized trial tested whether letting women initiate their own follow-up appointments, rather than attending scheduled clinic visits, would affect fear of recurrence. The results were somewhat counterintuitive: fear of recurrence actually decreased more in the group that kept traditional scheduled follow-up, suggesting that the structure and reassurance of regular appointments has psychological value beyond its medical utility.29PubMed. Patient-initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early-stage endometrial cancer If you find yourself preoccupied by the possibility of recurrence, that is normal and common, and it is worth discussing with your care team. Structured follow-up, psychosocial support, and clear guidance on which symptoms actually warrant urgent contact can help channel worry into something more manageable.